Arena Pharmaceutical (ARNA) 1.99 $ARNA
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 0.47 (-0.04), RTRX: 17.40 (-0.30), VVUS: 1.19 (-0.03), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.99 (-0.07)
Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 35.56 (-0.56), CBM: 50.78 (-1.50), ANIP: 52.05 (-1.64), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.99 (-0.07)
Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.99 (-0.07)
Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.99 (-0.07)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.67 (-0.18), INO: 10.62 (-0.39), VVUS: 1.19 (-0.03), TEVA: 53.01 (-0.30), ARNA: 1.99 (-0.07), PBYI: 33.41 (-0.43)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.72 (-0.40), JAZZ: 150.76 (-5.26), VVUS: 1.19 (-0.03), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday, May 9
PR Newswire - Mon May 02, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, May 9, 2016, to discuss first quarter 2016 financial results and provide a corporate update. Arena will issue a press release with its financial results after the NASDAQ Global Select Market closes that day.
ARNA: 1.99 (-0.07)
New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 10.26 (-0.50), ALIM: 1.72 (+0.03), ARES: 13.91 (+0.17), AXTA: 27.90 (+0.02), ARNA: 1.99 (-0.07)
Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 12:00PM CDT
Arena (ARNA) announced favorable results from a phase Ib study on its pain candidate, APD371.
EBS: 42.30 (-1.19), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals Reports Favorable Results from Phase 1b Multiple-Ascending Dose Clinical Trial of APD371
PR Newswire - Tue Apr 12, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from its Phase 1b multiple-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor with potential utility in the treatment of pain.
ARNA: 1.99 (-0.07)
New Strong Sell Stocks for April 7th
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:51AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXTI: 3.52 (-0.02), AMD: 4.32 (-0.20), ARES: 13.91 (+0.17), AWI: 40.09 (-1.98), ARNA: 1.99 (-0.07)
Stocks to Watch for Tuesday 3/22/2016, If You Choose
ACCESSWIRE - Tue Mar 22, 10:31AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 22, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. FBEC, ARNA, AXU, and LEU have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
ARNA: 1.99 (-0.07)
Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead
Arpita Dutt - Zacks Investment Research - Tue Mar 15, 9:15AM CDT
It could be challenging to pick winners in this "high risk and high returns" industry which is constantly growing and changing.
MDVN: 60.01 (-0.09), GILD: 84.45 (-1.32), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), ARNA: 1.99 (-0.07), REGN: 372.03 (-9.05)
Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Arpita Dutt - Zacks Investment Research - Fri Mar 11, 8:37AM CST
Is the dream run for the biotech sector finally over?
GILD: 84.45 (-1.32), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), MNTA: 11.67 (-0.13), ARNA: 1.99 (-0.07), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
New Strong Sell Stocks for March 8th
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 8:56AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
AMBA: 51.41 (-0.88), AXTI: 3.52 (-0.02), ARES: 13.91 (+0.17), ASC: 8.70 (-0.17), ARNA: 1.99 (-0.07)
Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January
George Budwell, The Motley Fool - Motley Fool - Tue Feb 09, 9:23AM CST
ARNA data by YCharts What: According to data provided by S&P Global Market Intelligence , shares of Arena Pharmaceuticals dropped by more than 17% in January. Given the lack of negative catalysts during the month, its poor showing...
OREX: 0.47 (-0.04), ARNA: 1.99 (-0.07)
Rheumatoid Arthritis Pipeline Review, H2 2015 - 200+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc73g7/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Rheumatoid ArthritisOverview - Therapeutics Development - Pipeline Products for Rheumatoid Arthritis - Overview - Pipeline Products for Rheumatoid Arthritis - Comparative Analysis - Rheumatoid Arthritis - Therapeutics under Development by Companies - Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes - Rheumatoid Arthritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Rheumatoid Arthritis - Products under Development by Companies - Rheumatoid Arthritis - Products under Investigation by Universities/Institutes - Rheumatoid Arthritis - Companies Involved in Therapeutics Development Companies Mentioned - 30 of the 200 Companies Featured - 3SBio Inc. - 4D Pharma Plc - 4SC AG - AB Science SA - AB2 Bio Ltd. - AbbVie Inc. - Ablynx NV - ACEA Biosciences, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegera Therapeutics Inc. - Alder Biopharmaceuticals Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Limited - Aprogen, Inc. - Arena Pharmaceuticals, Inc. - arGentis Pharmaceuticals, LLC - Arrien Pharmaceuticals, LLC - Arthrogen BV - Asahi Kasei Pharma Corp. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Avesthagen Limited - Avexxin AS - Axxam SpA - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited For more information visit http://www.researchandmarkets.com/research/mc73g7/rheumatoid
ALDR: 29.88 (+0.46), AZN: 27.97 (-0.99), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), ARNA: 1.99 (-0.07)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 0.47 (-0.04), RTRX: 17.40 (-0.30), VVUS: 1.19 (-0.03), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.99 (-0.07)
Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 35.56 (-0.56), CBM: 50.78 (-1.50), ANIP: 52.05 (-1.64), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.99 (-0.07)
Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.99 (-0.07)
Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.99 (-0.07)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.67 (-0.18), INO: 10.62 (-0.39), VVUS: 1.19 (-0.03), TEVA: 53.01 (-0.30), ARNA: 1.99 (-0.07), PBYI: 33.41 (-0.43)
Arena (ARNA) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Wed May 04, 7:07AM CDT
Will Arena (ARNA) continue with its earnings streak in Q1?
OVAS: 5.72 (-0.40), JAZZ: 150.76 (-5.26), VVUS: 1.19 (-0.03), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday, May 9
PR Newswire - Mon May 02, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, May 9, 2016, to discuss first quarter 2016 financial results and provide a corporate update. Arena will issue a press release with its financial results after the NASDAQ Global Select Market closes that day.
ARNA: 1.99 (-0.07)
New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 10.26 (-0.50), ALIM: 1.72 (+0.03), ARES: 13.91 (+0.17), AXTA: 27.90 (+0.02), ARNA: 1.99 (-0.07)
Arena (ARNA) Gains, Pain Drug Positive in Early Stage Study
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 12:00PM CDT
Arena (ARNA) announced favorable results from a phase Ib study on its pain candidate, APD371.
EBS: 42.30 (-1.19), AMAG: 21.04 (-0.82), ANIK: 49.16 (+0.24), ARNA: 1.99 (-0.07)
Arena Pharmaceuticals Reports Favorable Results from Phase 1b Multiple-Ascending Dose Clinical Trial of APD371
PR Newswire - Tue Apr 12, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from its Phase 1b multiple-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor with potential utility in the treatment of pain.
ARNA: 1.99 (-0.07)
New Strong Sell Stocks for April 7th
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 9:51AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXTI: 3.52 (-0.02), AMD: 4.32 (-0.20), ARES: 13.91 (+0.17), AWI: 40.09 (-1.98), ARNA: 1.99 (-0.07)
Stocks to Watch for Tuesday 3/22/2016, If You Choose
ACCESSWIRE - Tue Mar 22, 10:31AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 22, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. FBEC, ARNA, AXU, and LEU have been added to our watchlist today. Continue reading to find out why. - To get daily alerts on top stocks on the OTCQB, OTCQX, Nasdaq, NYSE, and OTCBB, subscribe to our newsletter at DailyStockReporter.com.
ARNA: 1.99 (-0.07)
Why Investors Should Sell These Biotech Stocks & Buy Gilead Instead
Arpita Dutt - Zacks Investment Research - Tue Mar 15, 9:15AM CDT
It could be challenging to pick winners in this "high risk and high returns" industry which is constantly growing and changing.
MDVN: 60.01 (-0.09), GILD: 84.45 (-1.32), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), ARNA: 1.99 (-0.07), REGN: 372.03 (-9.05)
Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Arpita Dutt - Zacks Investment Research - Fri Mar 11, 8:37AM CST
Is the dream run for the biotech sector finally over?
GILD: 84.45 (-1.32), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), MNTA: 11.67 (-0.13), ARNA: 1.99 (-0.07), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
New Strong Sell Stocks for March 8th
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 8:56AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
AMBA: 51.41 (-0.88), AXTI: 3.52 (-0.02), ARES: 13.91 (+0.17), ASC: 8.70 (-0.17), ARNA: 1.99 (-0.07)
Here's Why Arena Pharmaceuticals Lost 17% of Its Value in January
George Budwell, The Motley Fool - Motley Fool - Tue Feb 09, 9:23AM CST
ARNA data by YCharts What: According to data provided by S&P Global Market Intelligence , shares of Arena Pharmaceuticals dropped by more than 17% in January. Given the lack of negative catalysts during the month, its poor showing...
OREX: 0.47 (-0.04), ARNA: 1.99 (-0.07)
Rheumatoid Arthritis Pipeline Review, H2 2015 - 200+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc73g7/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Rheumatoid ArthritisOverview - Therapeutics Development - Pipeline Products for Rheumatoid Arthritis - Overview - Pipeline Products for Rheumatoid Arthritis - Comparative Analysis - Rheumatoid Arthritis - Therapeutics under Development by Companies - Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes - Rheumatoid Arthritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Rheumatoid Arthritis - Products under Development by Companies - Rheumatoid Arthritis - Products under Investigation by Universities/Institutes - Rheumatoid Arthritis - Companies Involved in Therapeutics Development Companies Mentioned - 30 of the 200 Companies Featured - 3SBio Inc. - 4D Pharma Plc - 4SC AG - AB Science SA - AB2 Bio Ltd. - AbbVie Inc. - Ablynx NV - ACEA Biosciences, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegera Therapeutics Inc. - Alder Biopharmaceuticals Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Limited - Aprogen, Inc. - Arena Pharmaceuticals, Inc. - arGentis Pharmaceuticals, LLC - Arrien Pharmaceuticals, LLC - Arthrogen BV - Asahi Kasei Pharma Corp. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Avesthagen Limited - Avexxin AS - Axxam SpA - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited For more information visit http://www.researchandmarkets.com/research/mc73g7/rheumatoid
ALDR: 29.88 (+0.46), AZN: 27.97 (-0.99), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), ARNA: 1.99 (-0.07)
